4//SEC Filing
Maduck Sean 4
Accession 0001193125-25-196315
CIK 0001088856other
Filed
Sep 3, 8:00 PM ET
Accepted
Sep 4, 7:54 PM ET
Size
19.4 KB
Accession
0001193125-25-196315
Insider Transaction Report
Form 4
Maduck Sean
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2025-09-02$5.05/sh+20,000$101,000→ 27,681 total - Award
Common Stock
2025-09-02$71.38/sh+228$16,275→ 7,909 total - Sale
Common Stock
2025-09-02$70.84/sh−4,930$349,221→ 7,681 total - Sale
Common Stock
2025-09-02$70.38/sh−15,070$1,060,607→ 12,611 total - Tax Payment
Common Stock
2025-09-03$71.38/sh−233$16,632→ 7,904 total - Exercise/Conversion
Stock option (right to buy)
2025-09-02−20,000→ 1,986 totalExercise: $5.05Exp: 2026-05-02→ Common Stock (20,000 underlying) - Award
Common Stock
2025-09-02+228→ 8,137 total
Holdings
- 40,000(indirect: See Footnote)
Common Stock
- 59,717(indirect: See Footnote)
Common Stock
- 10,000(indirect: See Footnote)
Common Stock
Footnotes (13)
- [F1]Includes 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, and 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- [F10]Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
- [F11]Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee.
- [F12]Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
- [F13]Fully exercisable.
- [F2]This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction.
- [F3]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $69.72 to $70.715 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- [F4]Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.72 to $71.09 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- [F5]The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 2, 2025.
- [F6]In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
- [F7]Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
- [F8]These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
- [F9]The closing price on September 2, 2025 was used to calculate the withholding obligation.
Documents
Issuer
CORCEPT THERAPEUTICS INC
CIK 0001088856
Entity typeother
Related Parties
1- filerCIK 0001698310
Filing Metadata
- Form type
- 4
- Filed
- Sep 3, 8:00 PM ET
- Accepted
- Sep 4, 7:54 PM ET
- Size
- 19.4 KB